Off-label use of antibiotics in hospitalized patients: focus on tigecycline.

790. et al. DUET-2: week-48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. In: Abstracts of the Fifteenth Conference on Abstract 791. et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Switch from enfuvirtide to raltegravir in highly treatment-experienced HIV-1-infected patients: a randomized open-label non-inferiority trial (EASIER – ANRS 138). A Phase IIIb pilot study substituting darunavir/ritonavir (DRV/r) and etravirine (ETR) for enfuvirtide (ENF) and current PI in a suppressive regimen. Abstract P068. www.hiv9.com. 7. Matt S, Kakuda T, Hanley W et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor ral-tegravir in healthy subjects. two-period, crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. Abstract P4.3/02. www.eacs-conference2007.com. 9. Yazdanpanah YC, Fagard C, Descamps D et al. High rate of viro-logic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: Results of the ANRS 139 TRIO trial. A et al. Excellent short-term CD4 recovery with a PI-and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine. and ritonavir-boosted darunavir: a safe and successful rescue regimen for multi-drug resistant HIV-1 infection. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. Sir, Tigecycline is the first of a new class of antibiotics named glycylcyclines and is active in vitro against a variety of Gram-positive and Gram-negative organisms, including vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, extended-spectrum b-lactamase-producing Enterobacteriaceae and multidrug-resistant (MDR) Acinetobacter spp. 1 It has been approved by the US FDA for the treatment of complicated intra-abdominal infections (cIAIs), complicated skin and skin structure infections (cSSSIs) 1 and community-acquired bacterial pneumonia (CABP). 2 Notwithstanding these indications, tigecycline's pharmacological and microbiological profiles encourage physicians' use of the drug for off-label indications. The definition of off-label use is not limited to prescribing an antibiotic for an indication that is not approved by regulatory authorities. The off-label use of a medication may include other parameters such as age, …